What Is BZO on a Urine Test and What Do Results Mean?

BZO is the abbreviation for benzodiazepines on a urine drug screen, and seeing it flagged as positive means the test detected what it believes to be a benzodiazepine or one of its breakdown products in your sample. Benzodiazepines are a class of prescription sedatives that includes well-known names like diazepam (Valium), alprazolam (Xanax), lorazepam (Ativan), and clonazepam (Klonopin). The catch is that the screening test behind a BZO result is far from perfect: it can miss drugs that genuinely are benzodiazepines and occasionally flag drugs that are not. Understanding how the test works, and where it breaks down, makes a real difference in knowing what your result actually tells you.

How a BZO Screening Test Actually Works

Most urine drug screens, whether they are the instant cup-style tests used in clinics or the lab-based panels ordered in hospitals, rely on a technique called immunoassay. The test uses antibodies designed to bind to a specific target molecule. For the BZO panel, that target is usually oxazepam or nordiazepam, two metabolites that many common benzodiazepines produce as they are broken down by the liver. When enough of the target molecule is present in the urine sample, the antibody reaction triggers a signal, and the test reads positive.

Some labs add an extra preparation step before running the immunoassay: they break apart the glucuronide bonds that the body attaches to drug metabolites before excreting them. This hydrolysis step converts those conjugated metabolites back into the parent drug, making them easier for the antibody to detect and improving sensitivity for certain benzodiazepines that would otherwise be missed.¹ Whether or not that step happens before your sample is tested depends entirely on which lab or testing platform your provider uses.

Why BZO Tests Miss Some Benzodiazepines

This is the single most important thing to understand about a BZO urine screen: a negative result does not reliably rule out benzodiazepine use. Because the antibodies in most assays are tuned to detect oxazepam and nordiazepam, any benzodiazepine that does not produce those two metabolites has a much harder time triggering a positive. Alprazolam, clonazepam, lorazepam, and triazolam all follow different metabolic pathways and frequently produce false-negative results on standard BZO immunoassays.²

Clonazepam is a particularly stubborn case. Even when labs use hydrolysis and newer, more sensitive assay platforms to boost detection, the screen still misses samples containing clonazepam at a meaningful rate.³ If you are prescribed clonazepam and a drug test comes back negative for BZO, this does not mean the drug is not in your system. It means the test is poorly suited to finding it.

How large is this problem in real-world settings? A study comparing two commercial benzodiazepine assays in emergency department and compliance monitoring patients found that the older assay had a false-negative rate above 60%, meaning it missed more than half of the benzodiazepine-positive samples confirmed by mass spectrometry. A newer assay brought that false-negative rate down to roughly 27%, a significant improvement but still not close to reliable for clinical decision-making on its own.⁴ These numbers mean that even with the best available immunoassay screening, about one in four benzodiazepine-positive samples will still be reported as negative.

False Positives and What Causes Them

The flip side of missing real positives is flagging false ones. A BZO-positive result on a screening test does not always mean benzodiazepines are present. Other medications can interfere with the antibody reaction and produce a positive signal even though no benzodiazepine was taken.

Sertraline (Zoloft), a widely prescribed antidepressant, is one documented culprit. A two-year retrospective review of over 500 records at one institution found that 160 positive BZO screens were later proven false by confirmatory testing. Among the cases that could not be explained by an actual benzodiazepine prescription, sertraline was the most common medication associated with the false positive.⁵ Other medications reported to cause BZO false positives in immunoassay screens include the antihistamine oxaprozin and certain NSAIDs, though sertraline has the most documented association in the clinical literature.

The practical lesson here is straightforward: if you have a positive BZO screen and you have not taken a benzodiazepine, tell your provider what medications you are on, including antidepressants, and ask for confirmatory testing before any clinical or legal conclusions are drawn.

What Confirmatory Testing Does Differently

Confirmatory testing is the second stage that separates a genuine finding from a screening artifact. Instead of relying on antibodies, confirmatory methods use mass spectrometry, typically paired with liquid chromatography. This combination physically separates each compound in the sample and identifies it by its molecular weight and fragmentation pattern. The result is not “benzodiazepine detected,” but rather a specific identification: “diazepam detected at this concentration” or “7-aminoclonazepam detected,” for example.⁶

This specificity matters in several scenarios. In pain management or addiction treatment, a provider needs to know whether a patient is taking the specific benzodiazepine that was prescribed and not something else. In forensic or workplace contexts, the difference between a prescribed medication and an illicit substance can have serious consequences. Confirmatory testing answers these questions; the immunoassay screen by itself cannot.

Not every facility or testing situation automatically follows a positive screen with confirmatory testing. Rapid point-of-care cups used in some employment screenings may not trigger a confirmation step unless you request it. If a BZO result could affect your job, custody case, or medical treatment, it is worth asking explicitly whether mass spectrometry confirmation was performed.

Detection Windows Vary Enormously

One of the most common questions people have after learning about BZO testing is how long a benzodiazepine stays detectable. The honest answer is that it depends heavily on which specific drug was taken. Benzodiazepines range from ultra-short-acting compounds like triazolam, which may be undetectable within a day or two, to long-acting compounds like diazepam, which can leave detectable metabolites in urine for weeks after a single dose.

Diazepam is the extreme case. It has a prolonged elimination half-life on its own, and it also produces a cascade of active metabolites, including nordiazepam, temazepam, and oxazepam, each of which has its own extended half-life. These stacked metabolites prolong both the clinical effects and the detection window well beyond what the parent drug alone would produce.⁷ For someone taking diazepam daily over a period of weeks, metabolites can remain detectable in urine for a month or more after the last dose.

Shorter-acting benzodiazepines like lorazepam and alprazolam are typically detectable for a shorter window, often a few days after a single dose. But individual variation is significant. Factors like age, liver function, body composition, whether you are taking other medications that affect the liver enzymes responsible for breaking down benzodiazepines, and even genetic differences in drug metabolism all shift the window in one direction or another.⁸ Two people taking the same dose of the same drug can have genuinely different detection windows.

Designer Benzodiazepines and the Limits of Standard Panels

Over the past decade, a growing number of synthetic benzodiazepines that are not approved by any regulatory agency have appeared in the illicit drug supply. These compounds, sometimes called “designer benzodiazepines,” include substances like etizolam, flualprazolam, and clonazolam. They act on the same brain receptors as prescription benzodiazepines and carry similar risks of sedation, respiratory depression, and dependence, but they were never part of any approved pharmacopeia.

Because some of these designer compounds are structurally similar to prescription benzodiazepines, they may trigger a positive result on the standard BZO immunoassay screen. The problem comes at the confirmation stage. Most clinical mass spectrometry panels are designed to look for a specific list of known prescription benzodiazepines and their metabolites. If the confirming lab does not include the designer compounds on its panel, the positive screening result will come back as “unconfirmed,” and there is a real risk that the finding gets dismissed as a false positive when it was actually a true detection of a novel substance.⁹

Some designer benzodiazepines, on the other hand, are structurally different enough that they do not cross-react with immunoassay antibodies at all, meaning they will not trigger a positive BZO screen even at high concentrations.¹⁰ The net result is a messy detection landscape: some novel compounds flag the screen but escape confirmation, others dodge both steps entirely. Specialized high-resolution mass spectrometry panels exist that can identify these substances, but they are not yet routine outside of forensic toxicology or reference laboratories.

What a Positive or Negative BZO Result Should Mean to You

If your BZO screen is positive and you have a prescription for a benzodiazepine, the result is likely straightforward, though confirmatory testing can verify that the specific drug detected matches what was prescribed. If your screen is positive and you have not taken a benzodiazepine, the result needs confirmation before anyone acts on it. False positives are well-documented, and the screening test is not designed to be a definitive answer.

If your BZO screen is negative, the result is less reassuring than it sounds. Several commonly prescribed benzodiazepines, including alprazolam and clonazepam, are poorly detected by the standard assay. A negative screen in the context of known or suspected benzodiazepine use should prompt a provider to order confirmatory mass spectrometry testing rather than assume the drug is absent.

In compliance monitoring settings, such as pain management agreements or substance use treatment programs, both false positives and false negatives have real consequences. A false positive might lead to a patient being discharged from a program for a violation that never happened. A false negative might lead a provider to believe a patient is not using benzodiazepines when they are, missing a potentially dangerous combination with opioids. The evidence is clear that immunoassay alone is not sufficient for clinical decision-making in these populations.⁴

Sample Tampering and Integrity Checks

In settings where people have a reason to try to defeat a drug test, sample integrity becomes a concern. Research has shown that common household chemicals can interfere with immunoassay test strips used for BZO and other drug classes. Substances like bleach, vinegar, sodium nitrite, and commercial drain cleaners added to a urine sample at concentrations as low as about 5% by volume can generate false-negative results on both immunoassay screening and the test strips used to detect adulterants.¹¹

The immunochromatographic strip tests used for rapid point-of-care screening are especially vulnerable to this kind of adulteration.¹² Labs that handle forensic or workplace samples typically check for signs of tampering by measuring the sample’s temperature, pH, creatinine concentration, and specific gravity. Abnormal values on any of these indicators can flag the sample as potentially adulterated or substituted. Observed collections, where a staff member is present during the sample being provided, are another common countermeasure in high-stakes testing situations.

How Newer Assays Are Changing the Landscape

Immunoassay technology has not stood still. Newer assay platforms, like the Roche Benzodiazepines II (BNZ2) assay, have been engineered to detect a broader range of benzodiazepine metabolites, improving sensitivity for drugs that older platforms routinely missed. In a head-to-head comparison against a legacy assay in emergency department and monitoring patients, the newer platform roughly doubled the detection rate, pushing sensitivity from about 38% up to about 73%.⁴ That is a meaningful improvement, but the researchers themselves concluded that even the newer assay cannot replace mass spectrometry in populations where accurate benzodiazepine detection matters.

The trade-off with higher sensitivity is a modest increase in false positives. The newer assay had a false-positive rate just under 5%, compared to about 2.6% for the older, less sensitive assay. In most clinical settings, that trade-off favors the newer test, because missing a true positive is generally more dangerous than flagging a sample that needs confirmatory testing. But it means that if your sample was run on one of these more sensitive platforms, a positive screen is somewhat more likely to need confirmation before it can be trusted.

For labs and clinicians, the takeaway has been a gradual shift toward reflex testing protocols: the immunoassay screen acts as a quick filter, and any positive (and sometimes any negative in high-suspicion cases) automatically triggers confirmatory mass spectrometry. This two-step approach captures the speed of immunoassay and the precision of mass spectrometry without relying too heavily on either one alone.

Medications That Can Trip Up the BZO Panel

Beyond sertraline, a handful of other prescription and over-the-counter medications have been associated with false-positive BZO screens, though the documentation varies in strength. Efavirenz, an HIV medication, and some nonsteroidal anti-inflammatory drugs have appeared in case reports. The key variable is the antibody used in the specific assay kit: different manufacturers target slightly different molecular shapes, so a medication that causes a false positive on one brand of test may not cause one on another.

If you are taking any medication and are concerned about a BZO test result, the most useful thing you can do is provide a complete medication list to whoever ordered the test. Pharmacists and toxicologists maintain cross-reactivity tables that map which medications are known to interfere with specific assay platforms. When the interpreting clinician knows what you are taking, they can assess the likelihood of a false positive much more accurately than they could from the raw screening result alone.

It is also worth knowing that the timing of your last dose relative to the test matters. A sample collected during the peak excretion window will have a higher concentration of metabolites than one collected a few days later. For short-acting benzodiazepines that already have weak cross-reactivity with the assay, even a small timing difference can push the result from positive to negative. This is another reason that a single negative screen should not be treated as proof of abstinence.